Case Details
- Citation: [2012] SGHC 253
- Title: Novartis AG and another v Ranbaxy (Malaysia) Sdn Bhd
- Court: High Court of the Republic of Singapore
- Decision Date: 28 December 2012
- Case Number: Suit No 150 of 2011
- Tribunal/Court: High Court
- Coram: Lee Seiu Kin J
- Judgment Reserved: Yes
- Plaintiffs/Applicants: Novartis AG and another
- Defendant/Respondent: Ranbaxy (Malaysia) Sdn Bhd
- Patent in issue: Patent No SG120119 (“Patent”)
- Procedural basis for amendment: O 87A r 11(6) of the Rules of Court (Cap 322, R 5, 2006 Rev Ed) and s 83 of the Patents Act (Cap 221, 2005 Rev Ed)
- Statutory provision central to amendment: s 84(3)(a) of the Patents Act (no amendment allowed if it results in additional matter)
- Legal Areas: Patents and inventions; pharmaceutical patent litigation; amendment of patent specifications
- Statutes Referenced: Patents Act (Cap 221, 2005 Rev Ed); Rules of Court (Cap 322, R 5, 2006 Rev Ed); Medicines Act (Cap 176, 1985 Rev Ed)
- Counsel for Plaintiffs/Applicants: Tony Yeo, D K Rozalynne PG Dato Asmali and Dora Tay (Drew and Napier LLC)
- Counsel for Defendant/Respondent: Daniel Koh (Eldan Law LLP) (instructed) and Andrew Quirk (foreign counsel from Mirandah Law LLP)
- Length of judgment: 19 pages, 10,337 words
- Cases Cited (as provided in metadata): [2012] SGHC 253 (note: the extract also references multiple authorities within the reasoning)
Summary
In Novartis AG and another v Ranbaxy (Malaysia) Sdn Bhd ([2012] SGHC 253), the High Court considered an application by the patent proprietor (Novartis AG) and its exclusive licensee for leave to amend patent claims in the context of Singapore’s “early warning” regime for pharmaceutical product licences. The defendant, a pharmaceutical company seeking to import and market products in Singapore, opposed the amendment and maintained that the patent was invalid for anticipation by prior art.
The dispute, as narrowed at the hearing, focused on whether proposed amendments to claims 1 and 5 were permissible. The court applied the statutory constraint in s 84(3)(a) of the Patents Act, which prohibits amendments that result in the patent specification disclosing “additional matter” beyond what was clearly and unambiguously disclosed in the application as filed. Using the well-established “Bonzel” test, the court assessed the original disclosure against the amended claims through the eyes of the skilled addressee.
Ultimately, the court’s reasoning emphasised legal certainty for third parties: a patentee cannot improve its position by adding subject matter not originally disclosed, even if the amendment might be commercially or technically attractive. The decision provides practical guidance on how Singapore courts approach claim amendment in pharmaceutical cases, particularly where the invention relates to known active ingredients and the patent’s value lies in formulation and delivery characteristics.
What Were the Facts of This Case?
Novartis AG was the registered proprietor of Patent No SG120119, and the second plaintiff was its exclusive licensee. Ranbaxy (Malaysia) Sdn Bhd sought to import for marketing in Singapore pharmaceutical products known as Starval Tablets. The products’ compositions related to the plaintiffs’ patent subject matter, and the plaintiffs alleged that marketing the products in Singapore would infringe the patent.
Under s 12A(3)(a) of the Medicines Act, Ranbaxy was obliged to serve notices to the patent proprietor when applying to the Health Sciences Authority for product licences. The notices were intended to inform the patent proprietor that the proposed products could potentially infringe the patent and to prompt the proprietor to commence proceedings within a specified period. The defendant’s notices effectively triggered the plaintiffs’ need to act quickly to preserve their rights.
After receiving the requisite notice, the plaintiffs commenced suit and sought declarations that the patent would be infringed if the defendant’s products were imported and marketed in Singapore. In its defence and counterclaim, Ranbaxy challenged the patent’s validity, asserting that the invention was anticipated by prior art. Two prior art references were relied upon, designated DA1 and DA2 for the purposes of the judgment.
In response to the invalidity challenge, the plaintiffs sought to amend the patent claims. The stated objectives of the amendment were to “enhance clarity,” “highlight the inventive contributions,” and “reduce the number of claims.” The plaintiffs also sought to further distinguish the claims from the subject matter disclosed in the prior art references cited by the defendant. At the hearing, counsel agreed that the core issue was whether amendments to claims 1 and 5 were permissible; the other amendments were consequential to those changes.
What Were the Key Legal Issues?
The primary legal issue was whether the proposed amendments to claims 1 and 5 would contravene s 84(3)(a) of the Patents Act by adding “additional matter.” This required the court to compare what the patent application as filed disclosed with what the amended patent claims would disclose, and to determine whether any relevant subject matter had been added by amendment.
A secondary, practical issue was how the court should construe the patent disclosure and the amended claims through the eyes of the skilled addressee. Because the invention concerned pharmaceutical preparations and the delivery/absorption of a known active agent (valsartan), the amendment analysis depended heavily on whether the original specification clearly and unambiguously supported the particular formulation ranges and compositional limitations introduced or refined in the amended claims.
Although the broader litigation involved infringement and validity (including anticipation by prior art), the amendment application itself was governed by a distinct legal test. The court’s task was not to decide anticipation on the merits at that stage, but to determine whether the patentee was legally entitled to amend the claims without breaching the statutory prohibition on additional matter.
How Did the Court Analyse the Issues?
The court began by setting out the governing statutory framework. The plaintiffs’ application was brought under s 83(1) of the Patents Act, which confers discretion on the court to allow amendment of a patent specification in infringement or revocation proceedings, subject to s 84. However, that discretion is constrained by s 84(3), which provides that no amendment shall be allowed if it results in the specification disclosing additional matter or extends the protection conferred by the patent. In this application, only s 84(3)(a) was relevant.
To determine whether an amendment discloses additional matter, the court adopted the “Bonzel” test from Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553. The Bonzel formulation requires a three-step exercise: first, ascertain what is disclosed in the application as filed (explicitly and implicitly) through the eyes of the skilled addressee; second, ascertain what is disclosed in the patent as granted; and third, compare the two disclosures to decide whether any subject matter relevant to the invention has been added. The court stressed that the comparison is strict: subject matter will be added unless it is clearly and unambiguously disclosed in the application as filed, either explicitly or implicitly.
The court further endorsed the Bonzel test through local authorities including FE Global Electronics Pte Ltd v Trek Technology (Singapore) Pte Ltd [2006] 1 SLR(R) 874, Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429, and Main-Line Corporate Holdings Ltd v DBS Bank Ltd [2012] 4 SLR 147. It also drew on the elaboration in European Central Bank v Document Security Systems Incorporated [2007] EWHC 600, which clarified that the exercise is not an obviousness test. In other words, even if the amendment might be obvious to the skilled person, it is not permitted if it introduces subject matter not clearly and unambiguously disclosed in the original application.
Applying these principles, the court focused on the specific amendments to claims 1 and 5. The extract indicates that the patent relates to pharmaceutical preparations comprising an AT1 receptor antagonist or an AT2 receptor modulator, and that the invention is directed to treatment of conditions associated with increased AT1 receptors in sub-epithelial areas or increased AT2 receptors in epithelia. The specification also described potential uses across a wide range of respiratory and other diseases, including chronic obstructive pulmonary disease and other conditions.
However, the parties’ agreement on key technical points narrowed the factual and legal analysis. It was not disputed that valsartan is an active agent for which a separate patent subsists; microcrystalline cellulose is an excipient that improves performance of valsartan at certain dosages; and crospovidone is a disintegrant that breaks up the drug in the digestive system. The patent’s contribution, therefore, lay in how valsartan is delivered and absorbed—particularly through formulation and dosage characteristics—rather than in the chemical compound of valsartan itself.
Within this context, the proposed amendments to claims 1 and 5 introduced or refined compositional limitations and percentage ranges for microcrystalline cellulose and crospovidone, and the proportion of valsartan relative to microcrystalline cellulose. The court’s analysis would have required careful mapping between these amended numerical ranges and the original specification’s disclosure. Under Bonzel, the question is not whether the amended ranges could be derived by inference or by selecting from broader ranges, but whether the amended subject matter is clearly and unambiguously disclosed—explicitly or implicitly—in the application as filed.
Although the extract provided here truncates the remainder of the judgment, the structure of the reasoning is clear from the portion reproduced: the court first establishes the legal test, then identifies the precise amendments at issue, and then applies the strict “clear and unambiguous disclosure” standard to determine whether the amendments add matter. The court’s approach reflects the policy underlying s 84(3)(a): preventing a patentee from obtaining an unwarranted advantage by improving its position through amendments that third parties could not reasonably have anticipated from the original filing.
What Was the Outcome?
The extract does not include the final dispositive orders. However, based on the court’s framing of the dispute and its reliance on the strict Bonzel test for additional matter, the outcome would turn on whether the amended claim limitations in claims 1 and 5 were supported by the original specification in a manner that was “clearly and unambiguously” disclosed. In practice, this means that if the amended numerical ranges or compositional relationships were not directly and unambiguously derivable from the original disclosure, the court would be likely to refuse leave to amend under s 84(3)(a).
Conversely, if the original application as filed already disclosed the relevant formulation ranges (explicitly or implicitly) such that the skilled addressee would understand them as part of the invention, the court would likely grant leave to amend, subject to any further procedural and costs considerations under s 83 and the Rules of Court.
Why Does This Case Matter?
This decision is significant for patent practitioners in Singapore because it reinforces the strict approach to amendment under s 84(3)(a) of the Patents Act. The court’s reliance on Bonzel and its endorsement through multiple local cases underscores that amendment is not a mechanism to “fix” claim deficiencies by introducing new technical features or refined ranges that were not clearly disclosed at filing.
For pharmaceutical patent litigation, the case is particularly instructive. Pharmaceutical patents often involve known active ingredients combined with excipients and formulation parameters. Where the inventive contribution is tied to delivery, absorption, or performance improvements, claim amendments that adjust percentage ranges, ratios, or compositional limitations must be anchored in the original specification. Otherwise, the amendment risks being characterised as additional matter, undermining the patentee’s ability to respond to invalidity arguments based on prior art.
From a strategic perspective, the case highlights the importance of drafting and prosecution discipline. Applicants should ensure that the specification contains sufficient explicit and implicit disclosure to support potential future claim amendments. For defendants, the decision provides a robust legal basis to oppose amendments that attempt to narrow or reposition claims in a way that introduces subject matter not originally disclosed, thereby preserving legal certainty for third parties relying on the published application.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), in particular:
- s 83(1) (amendment of patent in infringement or revocation proceedings)
- s 84(3)(a) (no amendment allowed if it results in additional matter)
- Rules of Court (Cap 322, R 5, 2006 Rev Ed), in particular:
- O 87A r 11(6) (procedure for amendment in patent proceedings)
- Medicines Act (Cap 176, 1985 Rev Ed), in particular:
- s 12A(3)(a) (notice requirement for product licence applications)
Cases Cited
- Bonzel (T) and anr v Intervention Limited and anr (No 3) [1991] RPC 553
- FE Global Electronics Pte Ltd and others v Trek Technology (Singapore) Pte Ltd and another appeal [2006] 1 SLR(R) 874
- Martek Biosciences Corp v Cargill International Trading Pte Ltd [2011] 4 SLR 429
- Main-Line Corporate Holdings Ltd v DBS Bank Ltd [2012] 4 SLR 147
- European Central Bank v Document Security Systems Incorporated [2007] EWHC 600
- G1/93, Advanced Semiconductor Products (EPO Enlarged Board of Appeal) (referenced for the policy underlying Art 123(2))
Source Documents
This article analyses [2012] SGHC 253 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.